[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hereditary-transthyretin-mediated-hattr-amyloidosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hereditary-transthyretin-mediated-hattr-amyloidosis":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100442360","patisiran-lipid-nanoparticle-lnp-pregnancy-surveillance-program-100442360",false,"NCT05040373","Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program","Patisiran-LNP Pregnancy Surveillance Program","Inclusion Criteria:\n\n* Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy\n\nExclusion Criteria:\n\n* There are no exclusion criteria for participation in this program.","FEMALE",{"count":18,"type":19},10,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal\u002Fneonatal\u002Finfant outcomes in women exposed to patisiran-LNP.",[23,24],"Hereditary Transthyretin-mediated (hATTR) Amyloidosis","Polyneuropathy",[26,27,28,29,30],"Hereditary neuropathic amyloidosis","Familial amyloidosis","Amyloidosis","Amyloidosis senile","Cardiac amyloidosis","RECRUITING","2026-05-28",{"date":34,"type":35},"2026-06-01","ACTUAL",{"date":37,"type":35},"2020-08-01",{"date":39,"type":19},"2030-10-12",{"name":41,"class":42},"Alnylam Pharmaceuticals","INDUSTRY",7]